Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2

Jie Wang A1, Yufeng Tang2, Jingjing Zhang3

  • 1School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.

Redox Biology
|April 22, 2022
PubMed

Insights

Sirtuin 1 (SIRT1) protects against doxorubicin-induced cardiotoxicity by stabilizing sestrin 2 (SESN2). Activating the SIRT1-SESN2 pathway offers a novel therapeutic strategy for preventing heart damage.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Doxorubicin (DOX) induces cardiomyopathy, associated with decreased sirtuin 1 (SIRT1) expression.
  • The interaction between SIRT1 and sestrin 2 (SESN2) in DOX-induced cardiac injury remains unclear.

Purpose of the Study:

  • To investigate SIRT1's role and its regulatory interaction with SESN2 in DOX-induced cardiac injury.
  • To elucidate the underlying molecular mechanisms.

Main Methods:

  • Utilized DOX-treated cardiomyocytes and cardiac-specific Sirt1 knockout mice models.
  • Assessed effects of resveratrol (RES) treatment, SIRT1 overexpression, and Sesn2 knockdown/upregulation.
  • Investigated SESN2 ubiquitination and interaction with MDM2.

Main Results:

  • SIRT1 deficiency worsened DOX-induced cardiac dysfunction; SIRT1 activation (RES or overexpression) conferred protection.
  • SIRT1 protected against DOX-induced oxidative damage and apoptosis via SESN2.
  • SIRT1 activation reduced SESN2 ubiquitination by inhibiting the SESN2-MDM2 interaction, stabilizing SESN2.

Conclusions:

  • SIRT1 protects the heart from DOX toxicity by reducing SESN2 ubiquitination through the SIRT1-MDM2-SESN2 axis.
  • The SIRT1-SESN2 pathway represents a potential therapeutic target for DOX-induced cardiotoxicity.